Quick Answer
Amneal Pharmaceuticals, Inc. reported Cash and Equivalents of $282.03 million for fiscal year 2025.
Amneal Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $282.03M | +155.1% |
| 2024 | $110.55M | +20.8% |
| 2023 | $91.54M | +252.4% |
| 2022 | $25.98M | -89.5% |
| 2021 | $247.79M | -27.4% |
| 2020 | $341.38M | +125.8% |
| 2019 | $151.20M | -29.1% |
| 2018 | $213.39M | +187.7% |
| 2017 | $74.17M | — |
| 2017 | $0.00 | -100.0% |
| 2016 | $27.37M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $201.25M | +171.9% | +181.3% |
| June 30, 2025 | $71.54M | +63.5% | +20.9% |
| March 31, 2025 | $59.19M | +27.2% | -46.5% |
| December 31, 2024 | $110.55M | +20.8% | +49.4% |
| September 30, 2024 | $74.01M | -14.9% | +69.1% |
| June 30, 2024 | $43.77M | -59.9% | -5.9% |
| March 31, 2024 | $46.52M | -67.8% | -49.2% |
| December 31, 2023 | $91.54M | +252.4% | +5.3% |
- Amneal Pharmaceuticals, Inc. showed an increase of +155.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Amneal Pharmaceuticals, Inc.’s cash and equivalents has grown by 930.5% (from $27.37 million to $282.03 million).
- The most recent figure is from Amneal Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: